OX40 Ligand/TNFSF4 Antibody (182609)

• Reactivity: Mu
• Applications: WB, ELISA(Cap)
• Clone: 182609
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Concentration: LYOPH

OX40 Ligand/TNFSF4 Antibody (182609) Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse OX40 Ligand/TNFSF4
  Gln49-Leu198
  Accession # P43488
• Specificity: Detects mouse OX40 Ligand/TNFSF4 in ELISAs and Western blots. In sandwich immunoassays, no cross-reactivity or interference with recombinant mouse (rm) OX40, recombinant human (rh) OX40 Ligand, rmFas Ligand, rmLIGHT, or rhLIGHT is observed. In Western blots, 100% cross-reactivity with rmTNF‑ alpha is observed, 15‑30% with rmTRANCE and rmTRAIL is observed, and no cross-reactivity with rmBAFF, rmEDA, rmGITR Ligand, rmLIGHT, rmTWEAK, rmFas Ligand, rhAPRIL, or rhOX40 Ligand is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: TNFSF4
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.5-2.0 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 1 ug/mL
• Application Notes: ELISA Capture: Mouse OX40 Ligand/TNFSF4 Antibody (Catalog # MAB12362)
  ELISA Detection: Mouse OX40 Ligand/TNFSF4 Biotinylated Antibody (Catalog # BAM12361)
  Standard: Recombinant Mouse OX40 Ligand/TNFSF4 (Catalog # 1236-OX)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for OX40 Ligand/TNFSF4 Antibody (182609)

• CD134 ligand
• CD134L
• CD252 antigen
• CD252
• Glycoprotein Gp34
• gp34
• OX40 antigen ligand
• OX40 Ligand
• OX40L
• OX-40L
• OX4OL
• TAX transcriptionally-activated glycoprotein 1
• tax-transcriptionally activated glycoprotein 1 (34kD)
• tax-transcriptionally activated glycoprotein 1, 34kD
• TNFSF4
• tumor necrosis factor (ligand) superfamily, member 4
• tumor necrosis factor ligand superfamily member 4
• TXGP1

Background

OX40 Ligand (OX40L), also known as gp34, is a type II transmembrane glycoprotein belonging to the TNF superfamily. Murine OX40L cDNA encodes a 198 amino acid (aa) protein comprised of a 28 aa N-terminal cytoplasmic domain, a 20 aa transmembrane segment, and a 150 aa C-terminal extracellular domain (1). Human and mouse OX40L share 46% sequence identity at the amino acid level (1). OX40L is expressed on activated antigen presenting cells such as B cells, macrophages, dendritic cells, and on endothelial cells at the site of inflammation. The receptor for OX40L is OX40 (CD134) which is expressed predominantly on activated CD4⁺ T cells. Expression of OX40 is transient following engagement of T cell receptors (2). Ligation of OX40L by OX40 stimulates proliferation and differentiation of activated B cells, and increases immunoglobulin secretion (3, 4). The expression of OX40L on B cells is up‑regulated by CD40 ligation (3). Engagement of the OX40‑OX40L system has co-stimulatory effects on T cells by stimulating the production of cytokines by T helper cells and increasing the survival of memory T cells (2, 5). Blocking of the OX40‑OX40L interaction in vitro inhibits co-stimulation resulting in decreased T cell proliferation and adhesion of T cells to endothelial cells. Inhibition of the OX40‑OX40L interaction in disease models has beneficial effects in acute graft-versus-host disease, inflammatory bowel disease and decreases the development of collagen-induced arthritis and experimental leishmaniasis (6).

1. Baum, P.R. et al. (1994) EMBO J. 13:3992.
2. Gramaglia, I. et al. (1999) J. Immunol. 161:6510.
3. Stuber, E. et al. (1995) Immunity 2:507.
4. Malstrom, V. et al. (2001) J. Immunol. 166:6972.
5. Maxwell, J.R. et al. (2000) J. Immunol. 164:107.
6. Weinberg, A.D. (2002) Trends Immunol. 23:102.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: TNFSF4
• Uniprot:
  • P43488()